LUNG-CANCER RISK, OCCUPATIONAL EXPOSURE, AND THE DEBRISOQUINE METABOLIC PHENOTYPE
- 1 July 1989
- journal article
- research article
- Vol. 49 (13) , 3675-3679
Abstract
The risk of lung cancer in smokers was examined based on the debrisoquine metabolic phenotype and on exposure to occupational lung carcinogens, specifically asbestos and polycyclic aromatic hydrocarbons. Extensive metabolizers of debrisoquine are at a 4-fold increased risk for lung cancer compared to poor metabolizers, after adjustment for age, sex, and smoking (pack-years), when only occupationally unexposed subjects are considered. Increased risk related to the debrisoquine metabolic phenotype was greatest for squamous and small cell histologies, and least for the adenocarcinoma subtype. Men with a history of exposure to occupational carcinogens had significantly increased risk of lung cancer (relative risk = 2.8), after adjustment for age and smoking. Considering the combined effect of the high risk extensive metabolizers debrisoquine metabolic phenotype and likely occupational exposure to asbestos, the relative excess risk for lung cancer was 18-fold. This finding is consistent with a synergism in risk between the ability to extensively metabolize debrisoquine and occupational exposure to lung carcinogens in male smokers. Debrisoquine phenotyping had potential for identifying carcinogen-exposed workers at high risk of lung cancer.This publication has 8 references indexed in Scilit:
- Polymorphic debrisoquin hydroxylation in 757 Swedish subjectsClinical Pharmacology & Therapeutics, 1988
- Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.Proceedings of the National Academy of Sciences, 1988
- Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidationBiochemical Pharmacology, 1987
- Chromosomal assignment of human cytochrome P‐450 (debrisoquine/sparteine type) to chromosome 22.British Journal of Clinical Pharmacology, 1987
- Debrisoquine oxidation in an Australian population.British Journal of Clinical Pharmacology, 1986
- Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populationsClinical Pharmacology & Therapeutics, 1985
- A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquinClinical Pharmacology & Therapeutics, 1985
- A Population and Familial Study of the Defective Alicyclic Hydroxylation of Debrisoquine among EgyptiansXenobiotica, 1979